Get Our Top Trade Ideas Delivered Daily - 65% Off Now
get this deal
España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Our Top Trade Ideas Delivered Daily - 65% Off Now
get this deal
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Kymera Therapeutics
KYMR
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$49.79
0.76
1.55%
At Close: -
$49.79
0
0.00%
After Hours: Sep 20, 4:00 PM EDT
15 minutes delayed
Get Report
Comment
Kymera Therapeutics (KYMR) Forecast
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Kymera Therapeutics (NASDAQ:KYMR) Stock
Kymera Therapeutics Stock (NASDAQ: KYMR)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, September 09, 2024
Cracking The Code: Understanding Analyst Reviews For Kymera Therapeutics
Benzinga Insights
Monday, August 26, 2024
This BJ's Wholesale Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday
Avi Kapoor
Wolfe Research Upgrades Kymera Therapeutics t...
Benzinga Newsdesk
Tuesday, August 20, 2024
Kymera Therapeutics Raises $225M Via Upsized ...
Benzinga Newsdesk
Monday, August 19, 2024
Kymera Therapeutics shares are trading lower ...
Benzinga Newsdesk
Kymera Therapeutics Begins Public Offering Of...
Benzinga Newsdesk
Wednesday, August 14, 2024
Morgan Stanley Maintains Equal-Weight on Kyme...
Benzinga Newsdesk
Monday, August 12, 2024
Unveiling 6 Analyst Insights On Kymera Therapeutics
Benzinga Insights
Wells Fargo Maintains Equal-Weight on Kymera ...
Benzinga Newsdesk
Wednesday, August 07, 2024
Kymera Therapeutics' Cash Balance Of $702M Ex...
Benzinga Newsdesk
Kymera Therapeutics Q2 2024 GAAP EPS $(0.58) ...
Benzinga Newsdesk
Sunday, July 14, 2024
XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details
Lekha Gupta
Wednesday, July 10, 2024
Oppenheimer Maintains Outperform on Kymera Th...
Benzinga Newsdesk
Kymera Therapeutics Surges 23.4%: Is This an Indication of Further Gains?
Zacks
Tuesday, July 09, 2024
B. Riley Securities Maintains Neutral on Kyme...
Benzinga Newsdesk
Why Helen of Troy Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Avi Kapoor
Kymera shares are trading higher after the co...
Benzinga Newsdesk
Nvidia, Micron, Arlo Technologies And Other Big Stocks Moving Higher On Tuesday
Avi Kapoor
Monday, July 08, 2024
Kymera Intends To Expand Hidradenitis Suppura...
Benzinga Newsdesk
Monday, June 17, 2024
Cracking The Code: Understanding Analyst Reviews For Kymera Therapeutics
Benzinga Insights
HC Wainwright & Co. Reiterates Buy on Kymera ...
Benzinga Newsdesk
Friday, June 14, 2024
Kymera Therapeutics Shares New Clinical Data ...
Benzinga Newsdesk
Monday, June 03, 2024
HC Wainwright & Co. Reiterates Buy on Kymera ...
Benzinga Newsdesk
Reported Saturday, Kymera Therapeutics Showca...
Benzinga Newsdesk
Friday, May 24, 2024
Demystifying Kymera Therapeutics: Insights From 5 Analyst Reviews
Benzinga Insights
HC Wainwright & Co. Reiterates Buy on Kymera ...
Benzinga Newsdesk
Thursday, May 23, 2024
Kymera Therapeutics Plans To Present New Clin...
Benzinga Newsdesk
Wednesday, May 22, 2024
Kymera Therapeutics To Present New Preclinica...
Benzinga Newsdesk
Tuesday, May 14, 2024
Kymera Therapeutics Present's Clinical Data F...
Benzinga Newsdesk
Friday, May 03, 2024
Oppenheimer Maintains Outperform on Kymera Th...
Benzinga Newsdesk
Thursday, May 02, 2024
Kymera Therapeutics Q1 EPS $(0.69) Beats $(0....
Benzinga Newsdesk
Monday, April 22, 2024
Kymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
Benzinga Insights
Oppenheimer Initiates Coverage On Kymera Ther...
Benzinga Newsdesk
Monday, April 08, 2024
Kymera Therapeutics Reveals Preclinical Data ...
Benzinga Newsdesk
Friday, March 01, 2024
Truist Securities Maintains Buy on Kymera The...
Benzinga Newsdesk
Tuesday, February 27, 2024
Piper Sandler Maintains Overweight Rating for Kymera Therapeutics: Here's What You Need To Know
Benzinga Insights
Piper Sandler Maintains Overweight on Kymera ...
Benzinga Newsdesk
Friday, February 23, 2024
Breaking Down Kymera Therapeutics: 4 Analysts Share Their Views
Benzinga Insights
Thursday, February 22, 2024
Kymera Therapeutics Is Well-Capitalized With ...
Benzinga Newsdesk
Kymera Therapeutics Q4 EPS $(0.25) Beats $(0....
Benzinga Newsdesk
Earnings Scheduled For February 22, 2024
Benzinga Insights
Thursday, February 15, 2024
Wolfe Research Initiates Coverage On Kymera T...
Benzinga Newsdesk
Tuesday, January 09, 2024
Kymera Therapeutics shares are trading higher...
Benzinga Newsdesk
Kymera Therapeutics Outlines Key 2024 Objecti...
Benzinga Newsdesk
Friday, January 05, 2024
Kymera Therapeutics Priced $275M Public Offer...
Benzinga Newsdesk
Thursday, January 04, 2024
Kymera Therapeutics Commences Public Offering...
Benzinga Newsdesk
Kymera Therapeutics shares are trading higher...
Benzinga Newsdesk
Kymera Highlights Immunology Strategy and Eme...
Benzinga Newsdesk
Wednesday, January 03, 2024
B of A Securities Downgrades Kymera Therapeut...
Benzinga Newsdesk
Tuesday, December 19, 2023
Deep Dive Into Kymera Therapeutics Stock: Analyst Perspectives (4 Ratings)
Benzinga Insights
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch